studies

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), pembrolizumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-021, 2016 0.90 [0.42; 1.92] KEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88] KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93] KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92] KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85] KEYNOTE-189, 2018 0.49 [0.38; 0.64] KEYNOTE-407, 2018 0.64 [0.49; 0.84] KEYNOTE-598, 2020 1.08 [0.85; 1.37] 0.73[0.62; 0.85]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020871%4,862moderatenot evaluable deaths (OS) (extension)detailed resultsKEYNOTE-021, 2016 0.71 [0.45; 1.12] KEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81] KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90] KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88] KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18] KEYNOTE-189, 2018 0.56 [0.45; 0.70] 0.74[0.63; 0.86]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018672%3,735moderatenot evaluable PFS (extension)detailed resultsKEYNOTE-021, 2016 0.54 [0.35; 0.83] KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65] KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18] KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10] KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01] KEYNOTE-189, 2018 0.48 [0.40; 0.58] 0.71[0.53; 0.94]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018693%3,735moderatenot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-021, 2016 0.53 [0.31; 0.91] KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68] KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21] KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11] KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98] KEYNOTE-189, 2018 0.52 [0.43; 0.63] KEYNOTE-407, 2018 0.56 [0.45; 0.70] KEYNOTE-598, 2020 1.06 [0.86; 1.30] 0.73[0.58; 0.92]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020890%4,862moderateserious objective responses (ORR)detailed resultsKEYNOTE-021, 2016 3.06 [1.45; 6.45] KEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39] KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33] KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66] KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94] KEYNOTE-189, 2018 3.88 [2.61; 5.79] KEYNOTE-407, 2018 2.20 [1.57; 3.09] KEYNOTE-598, 2020 1.00 [0.72; 1.39] 1.71[1.22; 2.38]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020885%4,862moderateserious objective responses (ORR) (extension)detailed resultsKEYNOTE-021, 2016 2.80 [1.34; 5.83] KEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02] KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32] KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62] KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88] KEYNOTE-189, 2018 3.84 [2.58; 5.70] 1.73[1.15; 2.60]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018686%3,735moderatenot evaluable AE (any grade)detailed resultsKEYNOTE-189, 2018 4.04 [0.36; 44.82] KEYNOTE-407, 2018 1.20 [0.36; 3.96] 1.52[0.52; 4.45]KEYNOTE-189, 2018, KEYNOTE-407, 201820%1,165lownot evaluable AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.03 [0.73; 1.45] KEYNOTE-407, 2018 0.99 [0.70; 1.39] 1.01[0.79; 1.28]KEYNOTE-189, 2018, KEYNOTE-407, 201820%1,165lownot evaluable AE leading to death (grade 5)detailed resultsKEYNOTE-189, 2018 1.13 [0.56; 2.28] KEYNOTE-407, 2018 1.31 [0.69; 2.49] 1.23[0.76; 1.97]KEYNOTE-189, 2018, KEYNOTE-407, 201820%1,165lownot evaluable AE leading to treatment discontinuation (any grade)detailed resultsKEYNOTE-189, 2018 2.19 [1.31; 3.65] KEYNOTE-407, 2018 2.28 [1.45; 3.61] 2.24[1.59; 3.15]KEYNOTE-189, 2018, KEYNOTE-407, 201820%1,165lownot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsKEYNOTE-189, 2018 2.04 [1.16; 3.59] KEYNOTE-407, 2018 2.09 [1.28; 3.39] 2.07[1.43; 2.99]KEYNOTE-189, 2018, KEYNOTE-407, 201820%1,165lownot evaluable STRAE (any grade)detailed resultsKEYNOTE-021, 2016 3.47 [1.25; 9.62] KEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82] 1.76[0.55; 5.64]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016276%425moderatenot evaluable STRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 5.56 [1.49; 20.67] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72] 2.09[0.38; 11.45]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016283%425moderatenot evaluable TRAE (any grade)detailed resultsKEYNOTE-021, 2016 0.95 [0.29; 3.12] KEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58] KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26] 0.31[0.15; 0.65]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019374%1,676moderatenot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.04 [0.92; 4.52] KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51] KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39] 0.53[0.22; 1.29]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019390%1,676moderatenot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-021, 2016 0.52 [0.05; 5.86] KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11] KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92] KEYNOTE-407, 2018 1.70 [0.61; 4.75] 1.00[0.56; 1.77]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-407, 201840%2,234moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-021, 2016 0.76 [0.25; 2.35] KEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44] KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39] 0.87[0.62; 1.21]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%1,676moderatenot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-021, 2016 4.44 [0.48; 40.91] KEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29] KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66] 1.09[0.74; 1.61]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%1,676moderatenot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 4.32 [0.19; 97.73] 4.32[0.19; 97.73]KEYNOTE-021, 201610%121NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15] KEYNOTE-189, 2018 0.50 [0.03; 8.00] 1.24[0.16; 9.82]KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 201820%1,858lownot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21] 0.19[0.01; 2.53]KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019217%1,372moderatenot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 0.79 [0.27; 2.29] KEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28] KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12] 0.14[0.02; 0.86]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019388%1,676moderatenot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.97[0.02; 48.81]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05] 0.29[0.08; 1.05]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] KEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58] 0.68[0.05; 8.86]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 201620%425moderatenot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97] KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87] KEYNOTE-189, 2018 3.01 [0.15; 60.33] 3.64[0.78; 16.97]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 201830%2,162moderatenot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 1.00[0.10; 9.63]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%1,676moderatenot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] KEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27] KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60] 0.47[0.17; 1.27]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%1,676moderatenot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-189, 2018 1.00 [0.03; 29.86] 1.40[0.13; 15.46]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 201820%911lownot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 0.52 [0.02; 15.84] KEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11] KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77] 2.81[0.84; 9.40]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%1,676moderatenot evaluable Dizziness TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] 1.01[0.06; 16.31]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 201620%425moderatenot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 4.32 [0.19; 97.73] KEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00] KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36] 0.48[0.17; 1.36]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201937%1,676moderatenot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54] KEYNOTE-189, 2018 4.02 [0.21; 76.41] 7.53[0.96; 58.84]KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 201820%1,858moderatenot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] KEYNOTE-189, 2018 0.50 [0.01; 25.20] 1.05[0.16; 6.92]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 201840%2,283moderatenot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52] KEYNOTE-189, 2018 0.50 [0.01; 25.20] 2.21[0.31; 15.58]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 201830%2,162moderatenot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] KEYNOTE-189, 2018 2.00 [0.09; 44.56] 1.50[0.26; 8.82]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 201840%2,283moderatenot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.06; 17.21] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63] 1.64[0.38; 7.03]KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 201920%1,372moderatenot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.06; 17.21] KEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26] 1.64[0.59; 4.55]KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 201920%1,372moderatenot evaluable Increased lacrimation (TRAE grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33] KEYNOTE-189, 2018 1.00 [0.03; 29.86] 0.47[0.11; 2.06]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 201840%2,283moderatenot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] KEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82] 0.28[0.01; 11.52]KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019264%1,372moderatenot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.94[0.06; 57.80]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.94[0.06; 57.80]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.70[0.04; 11.17]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 201820%911lownot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] KEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21] KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21] 0.24[0.03; 1.65]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019316%1,676moderatenot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] KEYNOTE-189, 2018 6.06 [0.34; 109.04] 3.10[0.49; 19.65]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 201830%2,162moderatenot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.14 [0.19; 24.25] KEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35] KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14] 0.10[0.00; 2.04]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019380%1,676moderatenot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] KEYNOTE-189, 2018 2.00 [0.09; 44.56] 1.65[0.23; 11.94]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 201830%2,162moderatenot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 0.52 [0.02; 15.84] 0.52[0.02; 15.84]KEYNOTE-021, 201610%121NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76] 0.10[0.01; 1.76]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] 1.05[0.02; 53.86]KEYNOTE-021, 201610%121NAnot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43] 0.08[0.00; 1.43]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Pneumonia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] KEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97] KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36] KEYNOTE-189, 2018 1.00 [0.30; 3.35] 3.39[0.74; 15.55]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018455%2,283moderatenot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.02; 53.86] KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15] 2.35[0.21; 26.88]KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 201920%1,372moderatenot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] 0.97[0.02; 49.41]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52] 3.75[0.39; 35.67]KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 201920%1,372moderatenot evaluable Sepsis TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] 2.12[0.07; 64.42]KEYNOTE-021, 201610%121NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.06; 17.21] KEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98] KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96] KEYNOTE-189, 2018 1.00 [0.30; 3.35] 2.84[0.68; 11.82]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018446%2,283moderatenot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 0.52 [0.02; 15.84] KEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.45[0.06; 3.24]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%1,676moderatenot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 1.05 [0.14; 7.73] KEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02] KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75] 0.21[0.03; 1.28]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019348%1,676moderatenot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] KEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.78[0.08; 7.49]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 201830%2,162moderatenot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-021, 2016 2.12 [0.07; 64.42] KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.06; 15.71] KEYNOTE-042 (PDL1>1%), 2019 0.24 [0.01; 5.36] 0.76[0.13; 4.47]KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201930%1,676moderatenot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 10.24 [0.56; 188.30] 10.24[0.56; 188.30]KEYNOTE-407, 201810%558NAnot evaluable Alopecia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.33 [0.03; 3.22] 0.33[0.03; 3.22]KEYNOTE-407, 201810%558NAnot evaluable Anaemia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.07 [0.67; 1.71] KEYNOTE-407, 2018 0.72 [0.46; 1.11] KEYNOTE-598, 2020 1.14 [0.41; 3.20] 0.89[0.65; 1.20]KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 202030%1,728lownot evaluable Arthralgia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.03 [0.37; 11.17] KEYNOTE-598, 2020 2.01 [0.36; 11.05] 2.02[0.60; 6.74]KEYNOTE-407, 2018, KEYNOTE-598, 202020%1,121lownot evaluable Asthenia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.83 [0.78; 4.31] KEYNOTE-407, 2018 0.60 [0.21; 1.66] KEYNOTE-598, 2020 0.25 [0.03; 2.22] 0.84[0.30; 2.41]KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020355%1,728lownot evaluable Back pain AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.04; 5.51] 0.50[0.04; 5.51]KEYNOTE-598, 202010%563NAnot evaluable Colitis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.04 [0.50; 8.23] 2.04[0.50; 8.23]KEYNOTE-407, 201810%558NAnot evaluable Constipation AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 2.00 [0.22; 18.06] KEYNOTE-407, 2018 0.67 [0.11; 4.04] KEYNOTE-598, 2020 1.00 [0.14; 7.12] 1.02[0.33; 3.19]KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 202030%1,728lownot evaluable Cough AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] KEYNOTE-407, 2018 0.67 [0.11; 4.04] KEYNOTE-598, 2020 0.50 [0.02; 14.89] 0.61[0.14; 2.65]KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 202030%1,728lownot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 3.02 [0.36; 25.28] KEYNOTE-407, 2018 1.21 [0.37; 4.02] KEYNOTE-598, 2020 6.03 [0.30; 120.98] 1.76[0.66; 4.71]KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 202030%1,728lownot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.79 [0.71; 4.50] KEYNOTE-407, 2018 1.88 [0.69; 5.16] KEYNOTE-598, 2020 10.29 [1.31; 80.96] 2.25[1.07; 4.72]KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020318%1,728lownot evaluable Dyspnoea AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.67 [0.30; 1.48] KEYNOTE-407, 2018 3.04 [0.31; 29.44] KEYNOTE-598, 2020 0.87 [0.31; 2.43] 0.82[0.44; 1.50]KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 202030%1,728lownot evaluable Epistaxis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.01 [0.02; 50.94] 1.01[0.02; 50.94]KEYNOTE-407, 201810%558NAnot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 2.37 [0.89; 6.34] KEYNOTE-407, 2018 0.82 [0.33; 2.01] KEYNOTE-598, 2020 1.51 [0.42; 5.39] 1.38[0.71; 2.67]KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 2020320%1,728lownot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.02 [0.07; 60.40] 2.02[0.07; 60.40]KEYNOTE-407, 201810%558NAnot evaluable Hypophysitis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 4.05 [0.18; 90.23] 4.05[0.18; 90.23]KEYNOTE-407, 201810%558NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.02 [0.07; 60.40] KEYNOTE-598, 2020 1.00 [0.06; 16.01] 1.32[0.15; 11.35]KEYNOTE-407, 2018, KEYNOTE-598, 202020%1,121lownot evaluable Increase AST AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.52 [0.48; 13.09] 2.52[0.48; 13.09]KEYNOTE-598, 202010%563NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.28 [0.69; 7.50] 2.28[0.69; 7.50]KEYNOTE-598, 202010%563NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 4.07 [0.45; 36.67] 4.07[0.45; 36.67]KEYNOTE-407, 201810%558NAnot evaluable Lacrimation increased AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 0.50 [0.01; 25.20] 0.50[0.01; 25.20]KEYNOTE-189, 201810%607NAnot evaluable Myalgia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.02 [0.18; 22.43] 2.02[0.18; 22.43]KEYNOTE-407, 201810%558NAnot evaluable Nausea AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.40; 2.51] KEYNOTE-407, 2018 0.75 [0.17; 3.39] KEYNOTE-598, 2020 4.01 [0.18; 89.26] 1.01[0.47; 2.16]KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 202030%1,728lownot evaluable Neutropenia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.39 [0.84; 2.30] KEYNOTE-407, 2018 0.90 [0.61; 1.32] 1.08[0.71; 1.66]KEYNOTE-189, 2018, KEYNOTE-407, 2018246%1,165lownot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.52 [0.25; 9.15] 1.52[0.25; 9.15]KEYNOTE-407, 201810%558NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.03; 29.86] 1.00[0.03; 29.86]KEYNOTE-189, 201810%607NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.36 [0.72; 2.56] 1.36[0.72; 2.56]KEYNOTE-598, 202010%563NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 3.07 [0.61; 15.32] KEYNOTE-598, 2020 2.21 [0.83; 5.91] 2.42[1.05; 5.59]KEYNOTE-407, 2018, KEYNOTE-598, 202020%1,121lownot evaluable Pruritus AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.04; 5.51] 0.50[0.04; 5.51]KEYNOTE-598, 202010%563NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.00 [0.03; 29.86] KEYNOTE-407, 2018 1.01 [0.14; 7.20] KEYNOTE-598, 2020 6.03 [0.30; 120.98] 1.56[0.35; 6.84]KEYNOTE-189, 2018, KEYNOTE-407, 2018, KEYNOTE-598, 202030%1,728lownot evaluable Rash AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.17 [0.30; 4.56] KEYNOTE-598, 2020 16.38 [0.94; 286.59] 3.20[0.26; 39.60]KEYNOTE-189, 2018, KEYNOTE-598, 2020263%1,170lownot evaluable Severe skin reactions AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 3.04 [0.31; 29.44] 3.04[0.31; 29.44]KEYNOTE-407, 201810%558NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsKEYNOTE-189, 2018 1.15 [0.60; 2.21] KEYNOTE-407, 2018 1.07 [0.55; 2.08] 1.11[0.70; 1.77]KEYNOTE-189, 2018, KEYNOTE-407, 201820%1,165lownot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-01 01:57 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220 - treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561